Search

Your search keyword '"Hermanides, Rik"' showing total 46 results

Search Constraints

Start Over You searched for: Author "Hermanides, Rik" Remove constraint Author: "Hermanides, Rik"
46 results on '"Hermanides, Rik"'

Search Results

2. Relationship Between Severity of Ischemia and Coronary Artery Disease for Different Stress Test Modalities in the ISCHEMIA Trial

3. Factors Associated With Coronary Angiography Performed Within 6 Months of Randomization to the Conservative Strategy in the ISCHEMIA Trial

4. TransCatheter aortic valve implantation and fractional flow reserve-guided percutaneous coronary intervention versus conventional surgical aortic valve replacement and coronary bypass grafting for treatment of patients with aortic valve stenosis and multivessel or advanced coronary disease: The transcatheter valve and vessels trial (TCW trial): Design and rationale

6. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial

7. Sex Differences in Revascularization, Treatment Goals, and Outcomes of Patients With Chronic Coronary Disease: Insights From the ISCHEMIA Trial

8. TCT-140 Combined Coexistence of Multiple Vulnerable Plaque Features is Associated With Incremental Rates of Adverse Events in Patients With Diabetes Mellitus: New Insights From the COMBINE OCT-FFR Trial

9. Abstract 16390: Cost-effectiveness of a CYP2C19 Genotype-guided Antiplatelet Strategy in ST-elevation Myocardial Infarction Patients

11. A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction

12. TCT-311 Complicated Plaques Prevail in Longer Lesions of DM Patients, but Lesions’ Length Does Not Impact DM Patients’ Prognosis: Data From COMBINE OCT-FFR Trial

13. Risk, Clinical Course, and Outcome of Ischemic Stroke in Patients Hospitalized With COVID-19: A Multicenter Cohort Study

14. TCT-82 Thin-Cap Fibroatheroma Rather Than Any Lipid Plaques Increases the Risk of Cardiovascular Events: Insights From the COMBINE FFR-OCT Trial

15. TCT-89 Morphological Characteristics of Thin-Cap Fibroatheroma Lesions in Patients With and Without Future Adverse Events: Insights From the COMBINE (OCT-FFR) Study

16. Cost-effectiveness of a CYP2C19 Genotype-guided Antiplatelet Strategy in ST-elevation Myocardial Infarction Patients

17. TCT CONNECT-281 Clinical Outcomes of Optical Coherence Tomography Detected High-Risk Versus Low-Risk Coronary Atherosclerotic Lesions in Medically Treated Fractional Flow Reserve Negative Lesions in Diabetes Mellitus Patients: The COMBINE Trial

18. CLOPIDOGREL VERSUS TICAGRELOR AND PRASUGREL IN PRIMARY PERCUTANEOUS CORONARY INTERVENTION PATIENTS WITH A NORMAL FUNCTION CYP2C19 GENE: A SUB-STUDY FROM THE POPULAR GENETICS

19. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial

20. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial

21. Resolute zotarolimus‐eluting stent in ST‐elevation myocardial infarction (resolute‐STEMI): A prespecified prospective register from the DAPT‐STEMI trial

22. IMMEDIATE VERSUS DELAYED REVASCULARIZATION IN PATIENTS WITH TRANSIENT ST-ELEVATION MYOCARDIAL INFARCTION: 1-YEAR FOLLOW-UP OF THE RANDOMIZED CLINICAL TRANSIENT TRIAL

23. Resolute zotarolimus‐eluting stent in ST‐elevation myocardial infarction (resolute‐STEMI): A prespecified prospective register from the DAPT‐STEMI trial

25. TCT-111 Efficacy and safety of glycoprotein IIb/IIIa inhibitors on top of a potent P2Y12 inhibitor in STEMI: A pre-specified sub-analysis of the ATLANTIC trial

27. Early or late intervention in patients with transient ST-segment elevation acute coronary syndrome: Subgroup analysis of the ELISA-3 trial

30. TCT-266 Impact of elevated glycosylated hemoglobin (HbA1c) on admission on long-term Mortality in Patients with Unknown Diabetes Mellitus Presenting with acute myocardial infarction (STEMI or NSTEMI)

31. TCT-262 Clinical Outcomes of Deferred Revascularisation Using Fractional Flow Reserve in Patients With and Without Diabetes Mellitus

32. TCT-512 Fractional Flow Reserve-Guided Deferred Versus Complete Revascularisation in Patients With Diabetes Mellitus

33. Clinical outcomes of deferred revascularisation using fractional flow reserve in patients with and without diabetes mellitus

34. TCT-2 Early or late intervention in patients with transient ST-segment elevation acute coronary syndromes: subgroup analysis of the ELISA-3 trial

35. TCT-492 Clinical Outcomes of a Fractional Flow Reserve-Guided Revascularization Strategy in Patients With Diabetes Mellitus. Results from a Single Center Registry

39. Abstract 5489: Provisional (bail-out) Use versus Routine Use of Glycoprotein 2b/3a Blockers in Stemi: A Sub-analysis From the On-time 2 Trial

41. Resolute zotarolimus‐eluting stent in ST‐elevation myocardial infarction (resolute‐STEMI): A prespecified prospective register from the DAPT‐STEMI trial

43. TCT-130 Conduction Disturbances and Permanent Pacemaker Implantation After Myval Transcatheter Heart Valve or Contemporary Standard Valves (Sapien and Evolut) Implantation: Insights From the LANDMARK Trial.

44. TCT-1007 Computational Fluid Dynamics Analysis of the Optical Coherence Tomography Verified Thin Cap Fibroatheroma: Subanalysis From the COMBINE OCT-FFR Study.

45. TCT-915 Predictors of Conduction System Disturbances Resulting in a New Permanent Pacemaker Implantation Within the LANDMARK Trial.

46. Early or late intervention in patients with transient ST-segment elevation acute coronary syndrome: Subgroup analysis of the ELISA-3 trial.

Catalog

Books, media, physical & digital resources